Skip to main content
Erschienen in: Journal of Neuro-Oncology 2/2012

01.09.2012 | Clinical Study

Population-based survival data for brain tumors in Korea

verfasst von: Kyu-Won Jung, Heon Yoo, Hyun-Joo Kong, Young-Joo Won, Sohee Park, Seung Hoon Lee

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Primary brain tumors are relatively uncommon but particularly lethal cancers. Although survival is useful for monitoring the effects of early cancer detection and treatment, there are few population-based estimates of survival for subjects with brain tumors, especially in Asian countries. Using the Korea National Cancer Incidence Database, 4,721 newly diagnosed cases of histologically confirmed malignant primary brain tumors from 1999 to 2004 were analyzed for observed survival. For trend analyses of glioblastomas, we included 2,751 glioblastoma cases diagnosed between 1999 and 2007. We compared survival by age group and histological type by use of the Kaplan–Meier method. For all ages and all brain tumor types in Korea, five-year survival was 37.5 %. For each histological type of brain tumor survival of pediatric and younger adult populations was much better than that of older adults. Five-year survival for glioblastoma, astrocytoma, anaplastic astrocytoma, and oligodendroglioma was 8.9, 51.6, 25.2, and 73.5 %, respectively. Two-year survival for glioblastoma increased from 18.6 % for cases diagnosed in 1999–2001 to 21.3 % for cases diagnosed in 2002–2004 and to 24.7 % for cases diagnosed in 2005–2007. These results may help clinicians and patients to assess long-term prognoses for brain tumors, and the data presented here could serve as master control data set for single-arm clinical trials, especially in Asian populations.
Literatur
1.
Zurück zum Zitat Bauchet L, Rigau V, Mathieu-Daudé H, Figarella-Branger D, Hugues D, Palusseau L, Bauchet F, Fabbro M, Campello C, Capelle L, Durand A, Trétarre B, Frappaz D, Henin D, Menei P, Honnorat J, Segnarbieux F (2007) French brain tumor data bank: methodology and first results on 10,000 cases. J Neurooncol 84:189–199PubMedCrossRef Bauchet L, Rigau V, Mathieu-Daudé H, Figarella-Branger D, Hugues D, Palusseau L, Bauchet F, Fabbro M, Campello C, Capelle L, Durand A, Trétarre B, Frappaz D, Henin D, Menei P, Honnorat J, Segnarbieux F (2007) French brain tumor data bank: methodology and first results on 10,000 cases. J Neurooncol 84:189–199PubMedCrossRef
2.
Zurück zum Zitat CBTRUS (2011) Statistical report: primary brain tumors diagnosed in the United States, 2004–2007. The Central Brain Tumor Registry of the United States, Hindsdale CBTRUS (2011) Statistical report: primary brain tumors diagnosed in the United States, 2004–2007. The Central Brain Tumor Registry of the United States, Hindsdale
3.
Zurück zum Zitat Kaneko S, Nomura K, Yoshimura T, Yamaguchi N (1993) Trend of brain tumor incidence by histological subtypes in Japan: estimation from the Brain Tumor Registry of Japan, 1973–1993. J Neurooncol 60:61–69CrossRef Kaneko S, Nomura K, Yoshimura T, Yamaguchi N (1993) Trend of brain tumor incidence by histological subtypes in Japan: estimation from the Brain Tumor Registry of Japan, 1973–1993. J Neurooncol 60:61–69CrossRef
4.
Zurück zum Zitat Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, Jemal A, Anderson RN, Ajani UA, Edwards BK (2011) Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 103:714–736PubMedCrossRef Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, Jemal A, Anderson RN, Ajani UA, Edwards BK (2011) Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 103:714–736PubMedCrossRef
5.
Zurück zum Zitat Deorah S, Lynch CF, Sibenaller ZA, Ryken TC (2006) Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results program, 1973 to 2001. Neurosurg Focus 20(4): E1 Deorah S, Lynch CF, Sibenaller ZA, Ryken TC (2006) Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results program, 1973 to 2001. Neurosurg Focus 20(4): E1
6.
Zurück zum Zitat Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Park EC, Lee JS (2011) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat 43:1–11PubMedCrossRef Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Park EC, Lee JS (2011) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat 43:1–11PubMedCrossRef
7.
Zurück zum Zitat Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, Noh HI, Lee JK, Pisani P, Park JG, Members of the Regional Cancer Registries (2005) Nationwide cancer incidence in Korea, 1999–2001; first result using the national cancer incidence database. Cancer Res Treat 37:325–331PubMedCrossRef Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, Noh HI, Lee JK, Pisani P, Park JG, Members of the Regional Cancer Registries (2005) Nationwide cancer incidence in Korea, 1999–2001; first result using the national cancer incidence database. Cancer Res Treat 37:325–331PubMedCrossRef
8.
Zurück zum Zitat Lee CH, Jung KW, Yoo H, Park SH, Lee SH (2010) Epidemiology of primary brain and central nervous system tumors in Korea. J Korean Neurosurg Soc 48:145–152PubMedCrossRef Lee CH, Jung KW, Yoo H, Park SH, Lee SH (2010) Epidemiology of primary brain and central nervous system tumors in Korea. J Korean Neurosurg Soc 48:145–152PubMedCrossRef
9.
Zurück zum Zitat Gurney JG, Kadan-Lottick N (2001) Brain and other central nervous system tumors: rates, trends, and epidemiology. Curr Opin Oncol 13:160–166PubMedCrossRef Gurney JG, Kadan-Lottick N (2001) Brain and other central nervous system tumors: rates, trends, and epidemiology. Curr Opin Oncol 13:160–166PubMedCrossRef
10.
Zurück zum Zitat Reis L, Eisner M, Kosary C, Hankey B, Miller B, Clegg L, Edwards B (2000) SEER Cancer Statistics Review, 1973–1997. National Cancer Institute, Bethesda, MD Reis L, Eisner M, Kosary C, Hankey B, Miller B, Clegg L, Edwards B (2000) SEER Cancer Statistics Review, 1973–1997. National Cancer Institute, Bethesda, MD
11.
Zurück zum Zitat Nomura K (2000) Present status of brain tumor statistics in Japan. Int J Clin Oncol 5:355–360CrossRef Nomura K (2000) Present status of brain tumor statistics in Japan. Int J Clin Oncol 5:355–360CrossRef
12.
Zurück zum Zitat McCarthy BJ, Davis FG, Freels S, Surawicz TS, Damek DM, Grutsch J, Menck HR, Laws ER Jr (1998) Factors associated with survival in patients with meningioma. J Neurosurg 88:831–839PubMedCrossRef McCarthy BJ, Davis FG, Freels S, Surawicz TS, Damek DM, Grutsch J, Menck HR, Laws ER Jr (1998) Factors associated with survival in patients with meningioma. J Neurosurg 88:831–839PubMedCrossRef
13.
Zurück zum Zitat Sant M, Van der Sanden G, Capocaccia R, EUROCARE Working Group (1998) Survival rates for primary malignant brain tumours in Europe. Eur J Cancer 34(14 Spec No):2241–2247PubMedCrossRef Sant M, Van der Sanden G, Capocaccia R, EUROCARE Working Group (1998) Survival rates for primary malignant brain tumours in Europe. Eur J Cancer 34(14 Spec No):2241–2247PubMedCrossRef
14.
Zurück zum Zitat Davis FG, Freels S, Grutsch J, Barlas S, Brem S (1998) Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology, and end results (SEER) data, 1973–1991. J Neurosurg 88:1–10PubMedCrossRef Davis FG, Freels S, Grutsch J, Barlas S, Brem S (1998) Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology, and end results (SEER) data, 1973–1991. J Neurosurg 88:1–10PubMedCrossRef
15.
Zurück zum Zitat Barnholtz-Sloan JS, Sloan AE, Schwartz AG (2003) Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumor, 1973–1997. J Neurosurg 99:458–466PubMedCrossRef Barnholtz-Sloan JS, Sloan AE, Schwartz AG (2003) Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumor, 1973–1997. J Neurosurg 99:458–466PubMedCrossRef
16.
Zurück zum Zitat Darefsky AS, King JT Jr., Dubrow R (2012) Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of surveillance, epidemiology, and end results registries. Cancer 118(8): 2163–2172. doi:10.1002/cncr.26494 Darefsky AS, King JT Jr., Dubrow R (2012) Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of surveillance, epidemiology, and end results registries. Cancer 118(8): 2163–2172. doi:10.​1002/​cncr.​26494
17.
Zurück zum Zitat Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ, Weichselbaum RR, McCarthy BJ (2012) Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 107(1): 207–212. doi:10.1007/s11060-011-0738-7 Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ, Weichselbaum RR, McCarthy BJ (2012) Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 107(1): 207–212. doi:10.​1007/​s11060-011-0738-7
18.
Zurück zum Zitat Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, Rossetti AO, Lacombe D, Mirimanoff RO, Vecht CJ, Stupp R (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 77:1156–1164PubMedCrossRef Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, Rossetti AO, Lacombe D, Mirimanoff RO, Vecht CJ, Stupp R (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 77:1156–1164PubMedCrossRef
19.
Zurück zum Zitat Scoccianti S, Magrini SM, Ricardi U et al (2010) Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (Italian Association of Radiation Oncology). Neurosurgery 67:446–458PubMedCrossRef Scoccianti S, Magrini SM, Ricardi U et al (2010) Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (Italian Association of Radiation Oncology). Neurosurgery 67:446–458PubMedCrossRef
20.
Zurück zum Zitat Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5:79–88PubMed Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5:79–88PubMed
21.
Zurück zum Zitat Stark-Vance V (2005) Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma (Abstract). Neurooncology 7:369 Stark-Vance V (2005) Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma (Abstract). Neurooncology 7:369
22.
Zurück zum Zitat Meyer FB, Bates LM, Goerss SJ, Friedman JA, Windschitl WL, Duffy JR, Perkins WJ, O’Neill BP (2001) Awake craniotomy for aggressive resection of primary gliomas located in eloquent brain. Mayo Clin Proc 76:677–687PubMedCrossRef Meyer FB, Bates LM, Goerss SJ, Friedman JA, Windschitl WL, Duffy JR, Perkins WJ, O’Neill BP (2001) Awake craniotomy for aggressive resection of primary gliomas located in eloquent brain. Mayo Clin Proc 76:677–687PubMedCrossRef
23.
Zurück zum Zitat Sanai N, Mirzadeh Z, Berger MS (2008) Functional outcome after language mapping for glioma resection. N Engl J Med 358:18–27PubMedCrossRef Sanai N, Mirzadeh Z, Berger MS (2008) Functional outcome after language mapping for glioma resection. N Engl J Med 358:18–27PubMedCrossRef
24.
Zurück zum Zitat Cardinale R, Won M, Choucair A, Gillin M, Chakravarti A, Schultz C, Souhami L, Chen A, Pham H, Mehta M (2006) A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys 65:1422–1428PubMedCrossRef Cardinale R, Won M, Choucair A, Gillin M, Chakravarti A, Schultz C, Souhami L, Chen A, Pham H, Mehta M (2006) A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys 65:1422–1428PubMedCrossRef
25.
Zurück zum Zitat Larson DA, Suplica JM, Chang SM, Lamborn KR, McDermott MW, Sneed PK, Prados MD, Wara WM, Nicholas MK, Berger MS (2004) Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neurooncol 6:119–126 Larson DA, Suplica JM, Chang SM, Lamborn KR, McDermott MW, Sneed PK, Prados MD, Wara WM, Nicholas MK, Berger MS (2004) Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neurooncol 6:119–126
26.
Zurück zum Zitat Narayana A, Yamada J, Berry S, Shah P, Hunt M, Gutin PH, Leibel SA (2006) Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. Int J Radiat Oncol Biol Phys 64:892–897PubMedCrossRef Narayana A, Yamada J, Berry S, Shah P, Hunt M, Gutin PH, Leibel SA (2006) Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. Int J Radiat Oncol Biol Phys 64:892–897PubMedCrossRef
27.
Zurück zum Zitat Prisco FE, Weltman E, de Hanriot RM, Brandt RA (2002) Radiosurgical boost for primary high-grade gliomas. J Neurooncol 57:151–160PubMedCrossRef Prisco FE, Weltman E, de Hanriot RM, Brandt RA (2002) Radiosurgical boost for primary high-grade gliomas. J Neurooncol 57:151–160PubMedCrossRef
28.
Zurück zum Zitat Simon JM, Cornu P, Boisserie G, Hasboun D, Tep B, Hardiman C, Valery CA, Delattre JY, Dormont D, Baillet F, Mazeron JJ (2002) Brachytherapy of glioblastoma recurring in previously irradiated territory: predictive value of tumor volume. Int J Radiat Oncol Biol Phys 53:67–74PubMedCrossRef Simon JM, Cornu P, Boisserie G, Hasboun D, Tep B, Hardiman C, Valery CA, Delattre JY, Dormont D, Baillet F, Mazeron JJ (2002) Brachytherapy of glioblastoma recurring in previously irradiated territory: predictive value of tumor volume. Int J Radiat Oncol Biol Phys 53:67–74PubMedCrossRef
29.
Zurück zum Zitat Won YJ, Sung J, Jung KW, Kong HJ, Park S, Shin HR, Park EC, Ahn YO, Hwang IK, Lee DH, Choi JS, Kim WC, Lee TY, Yoo CI, Bae JM, Kim ON, Chung W, Kong IS, Lee DH, Lee JS (2009) Cancer statistics in Korea: incidence, mortality and survival in 2005. Cancer Res Treat 41:122–131PubMedCrossRef Won YJ, Sung J, Jung KW, Kong HJ, Park S, Shin HR, Park EC, Ahn YO, Hwang IK, Lee DH, Choi JS, Kim WC, Lee TY, Yoo CI, Bae JM, Kim ON, Chung W, Kong IS, Lee DH, Lee JS (2009) Cancer statistics in Korea: incidence, mortality and survival in 2005. Cancer Res Treat 41:122–131PubMedCrossRef
Metadaten
Titel
Population-based survival data for brain tumors in Korea
verfasst von
Kyu-Won Jung
Heon Yoo
Hyun-Joo Kong
Young-Joo Won
Sohee Park
Seung Hoon Lee
Publikationsdatum
01.09.2012
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 2/2012
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-012-0893-5

Weitere Artikel der Ausgabe 2/2012

Journal of Neuro-Oncology 2/2012 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.